William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform rating on AbbVie Inc. (NYSE:ABBV). The research firm remains confident about the company’s prospects following positive clinical trial results on a crucial obesity treatment.

William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities

The company announced top-line results from the Phase 1 multiple-ascending-dose study of ABBV-295. It is trialing the candidate long-acting amylin analog in the treatment of obesity. The results showed a 10% weight loss after 12 weeks in patients treated with the drug. The topline result is competitive across the amylin class at a time when the company is increasingly expanding its pipeline beyond oncology drugs.

Analysts at BMO have also touted the positive outlook for obesity drugs, which are expected to strengthen and diversify the company’s portfolio. The company has already announced a $380 million investment as it seeks to expand its manufacturing facilities while focusing on neuroscience and obesity drugs.

AbbVie has also delivered topline results from the Phase 3 AFFIRM study of Skyrizi for Crohn’s disease. The results also showed significant improvements in clinical remission and endoscopic response compared to Placebo.

AbbVie Inc. (NYSE:ABBV) is a global research-driven biopharmaceutical company that discovers, develops, and markets advanced therapies for complex, serious health conditions. It focuses on immunology, oncology, neuroscience, eye care, and aesthetics.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.